Advertisement

Topics

ICER Report Suggest AbbVie’s Elagolix Could Strain Healthcare Budgets

20:00 EDT 9 May 2018 | BioSpace

Not only does the company have to deal with the U.S. Food and Drug Administration’s three month PDUFA delay for elagolix, but now the watchdog organization, The Institute for Clinical and Economic Review (ICER), has released some disconcerting news over pricing.

Original Article: ICER Report Suggest AbbVie’s Elagolix Could Strain Healthcare Budgets

NEXT ARTICLE

More From BioPortfolio on "ICER Report Suggest AbbVie’s Elagolix Could Strain Healthcare Budgets"

Advertisement
Quick Search
Advertisement
Advertisement